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Abstract
Human herpesvirus 6B (HHV6B) infects over 90% of the population, and
normally establishes a latent infection, where episodes of reactivation are
asymptomatic. However, in immunocompromised patients HHV6B reactivation
is associated with high morbidity and mortality. Cellular immunotherapy has been
utilised against other herpesvirus in immunocompromised settings. However,
limited information on the immune response against HHV6B has hampered the
development of immunotherapy for HHV6B-driven disease. In this study, we have
analysed the cellular immune response against four HHV6B antigens in a panel of
30 healthy donors. We show that the base-line level of T cell reactivity in peripheral
blood is very low to undetectable. A short-term reactivation step enabled expansion
of T cell responses, and all donors responded to at least 1 antigen, but more
commonly 3 or 4. A hierarchy of immunogenicity was determined with antigens
U90 and U54 being co-dominant, followed by U11 and U39. Putative CD8þ T cell
epitopes were mapped to U90 and U11, predicted to be presented in the context of
HLA-A1, A29, B39 and C6. T cells reactive against these novel epitopes were able to
recognise virus-infected cells. Our data is supportive of the application and on-
going development of T cell immunotherapy against HHVB-driven disease in the
immunocompromised host.
Introduction
Human herpesviruses are ubiquitous pathogens that
generally cause self-limited disease in healthy individuals.
However, in the context of an immunosuppressed host
herpesvirus infection can lead to serious, often fatal disease
[1]. Adoptive T cell therapy has been utilised as a therapeutic
modality in immunocompromised individuals, such as
recipients of hematopoietic stem cell (HSCT) or solid organ
transplant (SOT), where the herpesviruses Epstein–Bar virus
(EBV) andHuman cytomegalovirus (HCMV) are important
drivers of disease [2–9]. However, this has only been possible
due to the in-depth knowledge and understanding of the
cellular immune response against these viruses [10, 11]. This
is in direct contrast to another herpesvirus, the b-
herpesvirus human herpesvirus 6 (HHV6), which is also a
significant pathogen associated with poor outcome in
situations such as HSCT and SOT [12, 13].
HHV6 exists as two species, HHV6A and HHV6B, with a
high level of nucleotide similarity [13–15]. The epidemiolo-
gy and clinical features of HHV6A infection are poorly
characterised [12]. By contrast, HHV6B is present world-
wide with greater than 90% of the population carrying the
virus [12]. Primary infection with HHV6B usually occurs
during infancy, and is associated with a self-limiting disease,
presenting as a febrile illness or exanthema subitum [16, 17].
After primary infection, HHV6B establishes a life-long latent
infection, and in immunocompetent individuals reactiva-
tion is generally asymptomatic [12]. However, in an
immunosuppressed patient, such as HSCT and SOT,
reactivation of HHV6B is associated with significant clinical
pathology, which includes graft versus host disease (GvHD)
and encephalitis, and can lead to increased mortality [18–
22]. Although assumed to be important for control of
HHV6B reactivation, details of the cell-mediated immune
response against HHV6B are only just beginning to be
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elucidated. Recent studies have only just started to map and
characterise the T cell responses against antigens from
HHV6B. T cells have been shown to be reactive against
antigens such as U11, U14, U54, U71 and U90, and HLA
Class I restricted epitopes identified and mapped to HLA-
A2, A3, B7 and B40 [23–26]. However, there is still a need to
continue to fully characterise the immune responses to
HHV6B and to expand the database of knowledge on T cell
targets and HLA restricting elements.
In the current study, we have analysed a cohort of healthy
donors for T cell responses to HHV6B antigens U90, U11,
U54 and U39, representing an immediate early antigen, two
viral tegument proteins and a viral envelope glycoprotein,
respectively [15]. In agreement with other reports, we show
that base-line levels of HHV6-specific T cells in peripheral
blood is very low or undetectable, but that reactive T cells can
be successfully expended in vitro by short-term stimulation
with appropriate antigenic peptides. Indeed, of 30 donors
analysed all were able to mount responses to at least one of
the four target antigens, with the majority of donors
responding to three or all four. We identify three novel
putative CD8þ T cell epitopes in U90, predicted to be
restricted through HLA-A1, -A29 and -B39, and one epitope
in U11, restricted through HLA-C6. Importantly, T cells
reactivated with these peptides were able to recognise
HHV6B-infected target cells highlighting their potential
clinical utility. The continual identification and characteri-
sation of the targets of HHV6-specific T cells is important for
the future development of T cell therapies against HHV6B
driven disease, and the data presented here is an important
addition.
Results
Ex vivo analysis of T cell responses to HHV6B U11,
U39, U54 and U90
Very little is known about which HHV6B antigens are
targeted by T cells during HHV6 infection, and how
immunogenic such antigens would be. Given the high degree
of homology between HHV6B and a second human b-
herpesvirus, HCMV, we set out to determine if T cell
responses could be detected directly ex vivo against HHV6B
antigens corresponding to known immunogenic HCMV
proteins.We focused on four antigens fromHHV6B, namely
U11, 39, U54 and U90, corresponding to HCMV antigens
pp150, gB, pp65 and IE1. PBMCs were isolated from a panel
of 30 donors, with a broad range of HLA backgrounds,
stimulated for 16 h with single tube 15-mer PepMixesTM for
each HHV6B antigen, and analysed for the frequency of
CD8þve, IFN-gþve and CD4þve, IFN-gþve cells by ICS. A
representative example of the flow cytometry analysis of
HHV6 antigen-specific CD8þve, IFN-gþve cells is shown
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Figure 1. Ex vivo analysis of T cell responses to HHV6B antigens U11,
U39, U54 and U90. T cell responses to HHV6B antigens U11, U39, U54
and U90 in peripheral blood were analysed in a panel of 30 healthy
donors by ICS for IFN-g after overnight stimulation with 15-mer
PepMixesTM. Cells were stained with mAbs for CD8 or CD4 and IFN-g,
followed by analysis by ﬂow cytometry. (A) A representative ﬂow
cytometry analysis for CD8þIFNgþ responses is shown for donor HD05.
The percentages of CD8þve IFN-gþve T cells are shown in the top right
hand quadrant. Analysis of PBMC stimulated with a PepMixTM for HCMV
IE1 is also shown. ConA stimulated PBMC was used as a positive control
(not shown). (B) The percentage of CD8þve IFN-gþve T cells for HHV6B
antigen U11, U39, U54 and U90 are shown for all donors (n¼ 30).
HCMV-seropositive donors (n¼ 15) were also analysed for responses to
four immunogenic HCMV antigens (IE1, IE2, pp65 and gB). The median
frequency is indicated with a bar. Data are shown after subtraction of the
background value for unstimulated cells. (C) The same panel of donors
were analysed for CD4þ IFNgþ T cells. The percentage of positive cells
are shown as in part (B).
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for donor HD05 in Figure 1A. For this donor responses
against the HHV6B antigens U11, U39 and U54 were
equivalent to background unstimulated cells. A detectable
response was seen against U90 (0.16%), although this was
significantly lower than the representative HCMV antigen,
IE1 (1.54%). Overall, for all donors the frequency of CD8þT
cells detected against the four HHV6B antigens was very low,
in most cases barely above detected levels (Fig. 1B). The
median values for U11, U39 and U54 were 0.00% IFNgþ
CD8þ T cells (ranges 0–0.04, 0–0.08, 0–0.1% respectively),
whereas the median value for U90 was 0.01% (range 0–
0.19%, n¼ 30). Only seven donors had levels detectable at
0.1% or above after subtraction of the unstimulated
background, six for U90 (donors HD03, 0.1%; HD05,
0.13%; HD09, 0.19%; HD13, 0.14%; HD20, 0.14%; and
HD30, 0.12%) and one for U54 (HD03, 0.1%). To ensure
that this cohort of donors could respond to herpesviruses, 15
HCMV seropositive donors were also analysed for responses
to four immunogenic antigens from HCMV (namely IE1,
IE2, gB and pp65). Good responses were detected against
IE1, pp65 and gB, with IE2 being recognised at low levels by a
small number of donors in this group. Overall median values
for the HCMV antigens were IE1 0.13%, IE2 0.00%, pp65
0.10% and gB 0.04% (ranges 0–1.5, 0–0.08, 0–1.9, 0–0.22%
respectively, n¼ 15, Fig. 1B).
Similarly, very low levels of HHV6 antigen-specific
CD4þve, IFN-gþve cellswere detected (Fig. 1C). Themedian
valueswereU110%(range 0–0.01%),U390.01%, (0–0.03%),
U54 0.02% (0–0.07%) and U90 0.01% (0–0.03%, n¼ 30).
Responses to HCMV IE1, IE2, gB and pp65 were also
measured, and found to be present at detectable levels in the
majority ofHCMV-seropositive donors tested,median values
for IE1 0.07% (0–0.52%), IE2 0.02% (0–0.25%), pp65 0.4%
(0.08–3.13%) and gB 0.24% (0–1.7%, n¼ 10, Fig. 1C).
Short-term in vitro stimulation expands T cell
responses against U11, U39, U54 and U90
On the assumption that T cells against these HHV6B
antigens were present but at barely detectable levels ex vivo,
we predicted that a short-term in vitro reaction would
expand these T cells such that we could begin to characterise
the responses in further detail. Using the individual 15-mer
PepMixesTM for U11, U39, U54 and U90, we stimulated
PBMC from 25 donors for 10 days before analysis of
expanded populations by direct ELISPOT using the
PepMixesTM. Figure 2A shows the data from 19 HCMV
seropositive donors (top panel) and 6 HCMV seronegative
donors (lower panel). We were able to detect IFNgþ cells by
ELISPOT against all antigens. In the HCMV seropositive
donors, U90 showed the highest frequency of IFNgþ cells,
with a median value of 134 SFC/105 input cells (range
0–376), with median responses to U54, U11 and U39 of 95
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Figure 2. Breadth of T cell responses speciﬁc for HHV6B antigens U11,
U39, U54 and U90 analysed by IFN-g ELISPOT after a short-term in vitro
expansion. (A) PBMC from 25 donors were stimulated with HHV6B
PepMixesTM and cultured for 10 days, with the addition of IL2 from day 3.
The frequency of HHV6B antigen-speciﬁc T cells was evaluated by IFN-g
ELISPOT. The data are presented for 19 HCMV seropositive donors (top
panel) and 6 HCMV seronegative donors (lower panel). Results are
presented as IFN-g spot forming cells (SFC)/105 input cells, after
subtraction of the background value for the negative control (DMSO
pulsed cells), with the median value indicated with a bar. (B) The number
of donors responding to each antigen is represented graphically, with the
percentage responding in brackets, and (C) The number of antigens, and
speciﬁc antigen, each donor responded to is shown. (D) To determine the
phenotype of T cells present in PepMixTM expanded populations, cells
were stained for CD4þ and CD8þ cells (see Supporting Information Fig.
S1). The mean frequency of CD3þ CD4þ and CD3þ CD8þ cells for each
antigen PepMixTM are shown (SEM, n¼ 8).
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(range 0–346), 90 (range 0–372) and 50 (range 0–186) SFC/
105 input cells, respectively (n¼ 19).We were able to expand
HHV6B-specific T cells from the HCMV-seronegative
donors supporting the conclusion that we are expanding
authentic HHV6B response rather than cross-reactive
HCMV T cells. There was a slight difference in the strength
of responses detected in these donors, with U39 showing the
strongest response with median value of 110 SFC/105 input
cells (range 0–120), followed by U54 106 (range 39–149),
U90 69 (range 10–286) and U11 53 (range 0–260) SFC/105
input cells (n¼ 6). However, when data from all donors were
combined the median responses were U90 96 (range 0–376)
SFC/105 input cells followed by U54 95 (range 0–346), U39
77 (range 0–186) and U11 66 (range 0–372) SFC/105 input
cells. When analysed individually all donors responded to at
least one antigen: 14 donors responded to all 4 antigens, 3
donors responded to 3 antigens, 6 responded to 2 and only 2
donors recognised only 1 (Fig. 2B). In total 21/25 donors
(84%) responded to both U54 and U90, 19/25 (76%)
responded to U11 and 18/25 (74%) responded to U39. Based
on the approaches used here, although the overall responses
were similar, a hierarchy could be established with U90 and
U54 being the most immunodominant, with very little
difference between them, followed by U11 and U39.
Since the IFNg ELISPOT does not discriminate between
reactive CD8þ and CD4þ T cells we next performed
phenotypic analyses of our polyclonal T cell populations (see
Supporting information Fig. S1). This revealed that for each
PepMixTM expanded T cell population, the majority of
CD3þ T cells were also CD4þ, with a mean frequency for
U11 of 63.5 10.8%; U39 66.3 12.4%; U54 61.6 12.9%,
U90 65.9 11.6% (n¼ 8). Correspondingly, lower values of
CD3þCD8þ cells were seen in the expanded populations for
each antigen, U11 21.5 11.0%; U39 20 8.9%; U54
27.9 8.9%, U90 20.1 9.1% (Fig. 2D).
Identification and HLA mapping of CD8þ T cell
epitopes in U90
Having shown that the circulating precursor frequency of
HHV6-directed T cells was low in peripheral blood, but that
reactive cells could be readily expanded by a short-term
stimulation in vitro, we next sought to identify and map
individual CD8þ epitopes. Polyclonal T cell populations
were expanded using the U90 PepMixTM from selected
donors shown to contain U90-specific responses (Fig. 2). To
ensure that we would maximise the possibility of identifying
CD8þ responses, expanded T cells were enriched for CD8þ
T cells by depletion of CD4þ cells. The first donor analysed
was donor HD53 (HLA-A29, B44, C5, C16), with a fourfold
enrichment of CD8þ T cells (increase from 16% to 67%)
achieved by depleting CD4þ T cells (Supporting Informa-
tion Fig. S2). These CD8-enriched cells were then analysed
by ELISPOT for IFNgþve cells by direct stimulation with 33
U90 mini pools of overlapping 15-mer peptides. The results
of the mini-pool screen are shown in Figure 3A, with two
strong responses identified against pool 3 and 29. Using the
2D grid representing the U90 mini pools, the peptide that is
present in both of these pools was identified as peptide 190,
KPSKKKIKLDRLPE (aa 766–780). The same expanded,
CD8-enriched T cells were then screened against peptide 190
on its own, along with the flanking 15-mer peptides (189 and
191, Fig. 3B). This confirmed that peptide 190 was
recognised by T cells from donor HD53, but neither 189
nor 191 (in agreement with the mini-pool screen data). To
map the minimal peptide epitope, overlapping 9-mer
peptides were synthesised spanning the peptide 190 sequence
and tested by ELISPOT against CD8-enriched T cells which
had been reactivated with the 15-mer peptide 190. Figure 3C
shows that the minimal epitope maps to the sequence
PSKSKKIKL (aa 765–773), termed PSK. To identify the HLA
restricting element, autologous and partially HLA-matched
target cells were pulsed with either the PSK peptide or
DMSO control and used as targets in T cell assays with
polyclonal T cell populations specific for PSK. Using
detection of IFNg secreted into the supernatant, we found
that autologous and HLA-A29 matched targets were
recognised by PSK-specific T cells, and while there was a
slight recognition of B44-matched targets above back-
ground, we predict that the PSK peptide is presented to T
cells in the context of HLA A29. One additional donor HLA-
A29 positive donor was available and to test if this donor
(HD33; HLAA11, A29, B39, B44, C9, C16) also responded to
the PSK peptide, PBMCs were reactivated with the PSK
peptide, cultured for 10 days in vitro before being screened
by ELISPOT. A PSK-specific response was identified in this
donor (Supporting Information Fig. S3), supporting this as a
novel U90-derived CD8þ T cell epitope, putatively
presented through HLA-A29.
Analysis of two further donors (HD10 and HD49) also
identified novel CD8þ T cell epitopes. Amini-pool screen of
expanded T cells, enriched for CD8þ cells, from donor
HD10 (HLA A1, A2, B8, B39) identified a number of
potential stimulating pools. The positive pools 5 and 31 were
selected for further analysis, where the common 15-mer was
peptide 226, EANHCFINHFVPIKT (aa 901–915, Support-
ing Information Fig. S4). Using peptide 226 and overlapping
peptides spanning this sequence, the response was mapped
to NHCFINHFV (NHC; aa 903–911), and shown to be
restricted through HLA B39 (Fig. 4A). Similar analysis of
CD8-enriched cells from donor HD49 (HLA A1, A2, B8,
B44, C5, C7) also identified a number of potential positive
pools, with the responses to pools 2 and 24 selected for
further analysis. The intersect between these pools was the
15-mer peptide 104, SICDLNIDPSESILL (aa 413–427,
Supporting Information Fig. S4). Using peptide 104 and
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overlapping 9-mer peptides, the response was mapped to
LNIDPSESI (LNI; aa 417–425), and shown to be restricted
through HLA A1 (Fig. 4B).
Our analysis also confirmed responses to previously
published epitopes as shown in Supporting Information
Figure S5, where CD8-enriched T cells from donor HD57
(HLA A2, B40(60), B50, C6, C10) were shown to recognize
the recently published B40-restricted peptides VEESIKEIL
(VEE; aa 39–47) and FESLLFPEL (FES; aa 57–67) [25].
(Supporting Information Fig. S5A and B). Two additional
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B40-positive donors (HD05 and HD30) were also shown to
have responses targeting these peptides (Supporting Infor-
mation Fig. S5C).
Identification and HLA mapping of a CD8þ T cell
epitope in U11
We applied the same strategy to mapping CD8þ T cell
responses in HHV6B U11. Polyclonal T cell populations
were expanded from donor HD32 (HLA-A1, A33, B37, B58,
C6, C9), using the U11 PepMixTM, enriched for CD8þ cells
and analysed by ELISPOT for IFNgþve cells by stimulation
with 30 U11 mini-pools of overlapping 15-mer peptides
(Fig. 5A). A number of responses were identified, with two
strong responses identified against pool 5 and 22 selected for
further analyses. The intersect of these pools maps to 15-mer
85, PLKTQRRHKFPESDS (aa 337–351, Fig. 5A). This 15-
mer was recognised by T cells, as was the 9-mer
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overlapping 9-mer peptides spanning the 15-mer peptide 104 (SICDLNIDPSESILL), identifying the minimal peptide as LNIDPSESI (left hand panel).
Autologous or partially HLA-matched target cells were pulsed with either the LNIDPSESI 9-mer or DMSO, and used as targets in T cells assays with U90
PepMixTM expanded T cells, at an E/T ratio of 20:1 (right hand panel). T cell recognition of targets was monitored by detection of IFN-g in culture
supernatants by ELISA. Results for ELISPOT experiments are presented as IFN-g spot-forming cells (SCF) per 105 input cells and are shown as the mean of
triplicate wells (SD). Data from ELISA experiments are presented as pg/mL, and are shown as the mean of triplicate wells (SD).
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LKTQRRHKF (aa 338–346), termed LKT (Fig. 5B). Re-
sponses were also seen against other 9-mers (e.g. QRR and
RRH), suggesting that this 15mer may contain a second
independent epitope (Fig. 5B), but this was not investigated
further. LKT-specific T cells were then shown to recognise
peptide-pulsed target cells carrying both HLA-B37 and -C6
alleles (Fig. 5C). Based on the peptide binding motif of these
alleles, where there is strong preference for a basic anchor
residue at position 2 for HLA-C6 as opposed to an acidic
residue for B37, we propose the HLA restricting element of
LKT is HLA-C6.
HHV6B U90 and U11-specific T cells recognise
virus-infected cells
With the ultimate objective of using these cells clinically, it
was important to confirm that these new HHV6B-specific T
cell epitopes could recognise endogenously expressed
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Figure 5. Identiﬁcation of the CD8þ T cell epitope LKTQRRHKF in HHV6B U11, restricted through HLA-C6. (A) Polyclonal T cells from donor HD32 (HLA-A1,
A33, B37, B58, C6, C9) expanded in vitro by stimulation with the U11 PepMixTM were depleted of CD4þ cells before being screened by IFN-g ELISPOT using
U11mini-pools. The 30mini pools contain 212 overlapping 15-mers representing the entire U11 protein, with each 15-mer present in two pools (shown in the
grid). PepMixesTM representing U11 and BK polyomavirus VP1 were used as positive and negative controls respectively. A pool was considered positive if the
response was 2.5-fold greater than background, indicated by the dashed line. Two strongly positive pools (5 and 22) are boxed and the common 15-mer,
peptide 85 (PLKTQRRHKFPESDS), highlighted by arrows. (B) Individual overlapping 9-mer peptides spanning the 15-mer peptide 85 were tested against the
same expanded T cell population identifying the minimal peptide as LKTQRRHKF. Results for ELISPOT experiments are presented as IFN-g spot-forming cells
(SCF)/105 input cells, are shown as the mean of triplicate wells (þ/SD). (C) Autologous or partially HLA-matched target cells were pulsed with either the
LKTQRRHKF 9-mer peptide or DMSO, and used as targets in T cells assayswith U11 PepMixTM expanded total T cells, at an E/T ratio of 10:1. T cell recognition of
targetswasmonitored by detectionof IFN-g in culture supernatants by ELISA.Data are presented as pg/mL, and are shownas themeanof triplicatewells (SD).
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antigen. Thus, T cell populations were expanded using
individual 9-mers representing U90 PSK, LNI andNHC, and
U11 LKT and the expanded T cells were tested for
recognition of HHV6B-infected autologous cells lines.
Figure 6A shows the data for U90 PSK, where there is clear
recognition of HHV6B-infected cells to levels equivalent to
peptide pulsed targets. Staining of target cells confirms that
they are efficiently infected with HHV6B virus (Supporting
Information Fig. S6). Target cell recognition for LNI, NHC
and LKT effectors is shown in Figure 6B–D, with all T cell
lines recognising HHV6B virus-infected cells to similar levels
as the peptide-pulsed controls. Whilst the expanded T cell
cultures used here will undoubtedly contain other non-
HHV6B specific populations of T cells, we do not believe that
they contribute to the recognition observed.
Discussion
HHV6B reactivation is a significant clinical problem after
HSCT and SOT, and is associated with GvHD, encephalitis
and increased mortality. Manipulation of cellular immune
responses against other herpesviruses, such as EBV and
HCMV, has proved to be successful in treating clinical
disease driven by reactivation of these viruses in HSCT and
SOT patients. This suggests that T cell immunotherapy
should also be considered as a treatment option for patients
with HHV6B reactivation after transplant. Currently, this is
limited by a paucity of detailed information on the cellular
immune response to this virus, such that althoughHHV6B is
known to induce immune responses, there is little detailed
information on target antigens, T cell epitopes or HLA
restriction elements. This detail is a key requirement to
understand the role of cellular immunity in controlling
HHV6B reactivation, and will feed into development of
future immunotherapy against this virus. In this report, we
have investigated the T cell response toHHV6B infection in a
group of healthy individuals, and mapped four putative
novel CD8þ antigenic peptides to U90 and U11 predicted to
be presented in the context of HLA alleles A1, A29, B39 and
C6 (Table 1).
We started by addressing the level of HHV6-specific T cells
in peripheral blood, against four antigens, U11, U39, U54 and
U90. These antigens were chosen to represent antigens
expressed immediately upon infection (U90) or present as
part of the virion (tegument proteins U11 and U54, and viral
glycoprotein U39), and being functional homologues of
immunogenic HCMV antigens (IE1, pp150, pp65 and gB,
respectively) [15, 27]. After overnight stimulation with whole
antigen PepMixesTM, ICS was used to identify CD8þIFNgþ
and CD4þIFNgþ T cells. In our panel of 30 healthy donors
responses were very low or undetectable. CD8þIFNgþ
responses over 0.1% were only observed against U90 in six
donors, and U54 in one donor, with median values of 0.01%
for U90 and 0.00% for U11, U39 and U54. Levels of
CD4þIFNgþ cells were also low but overall had higher
median values for 3 out of the 4 antigens (U11 0.00%, U90
0.01%, U39 0.01% and U54 0.02%). In contrast, significant
levels of HCMV IFNgþ CD4þ and CD8þ responses to
comparable antigens were observed in HCMV seropositive
donors within this group. Thus, confirming we are able to
detect herpesvirus-specific responses in our donors directly ex
vivo, and that the very low levels of HHV6B-specific response
are a feature of the immune response to HHV6B in these
donors. Indeed, the levelsofHHV6T-cell reactivitydetected in
peripheral blood in study is in agreement with previous
publications using viral infected cell lysates [23, 28–30] and
more recentlyusinga similarPepMixTMstimulationapproach
[25, 26]. It is known that T cell immunity to HCMV increases
withage [31].Thishasnotyetbeen shownforHHV6B, and the
agerangeofourcohortofdonors,22–63yearswithamedianof
39 years,wasnot sufficient to address this point.However, our
study does indicate that the responses detectable in peripheral
blood in the young (20–40 years) and middle aged (40–60
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Figure 6. HHV6B U90- and U11-speciﬁc T cells recognise virus-infected
target cells. (A) Polyclonal PSK-speciﬁc T cell effectors generated by
reactivation of donor HD53 PBMCwith the U90 9-mer peptide PSK were
tested in T cell assays against autologous PHA blasts infectedwith HHV6B
strain Z29 or mock infected, at the indicated E:T ratios. Control targets
PHA blasts pulsed with either the PSK peptide or DMSO. (B, C and D)
Polyclonal T cell effectors generated by reactivation of donor PBMC with
the individual 9-mer peptides U90 9-mer NHC and LNI, and U11 LKTwere
tested in T cell assays against autologous PHA blasts infectedwith HHV6B
strain Z29 or mock infected. Control targets PHA blasts pulsed with the
individual 9-mer peptide or DMSO. T cells were used at an E/T ratio of
10:1. T cell recognition of target cells was determined by measuring
release of IFN-g in to the supernatant by ELISA. Results are the mean of
experimental triplicates (SD) and expressed as pg/mL.
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years) are very weak. Further detailed investigations will be
required to determine the strength ofHHV6BT cell responses
in the elderly (>60 years). We subsequently showed using
ELISPOT analysis that IFNgþ T cell responses could be
expandedbystimulationwithPepMixesTM invitro followedby
a short-term culture. Using this approach we did not
differentiate between CD4þ and CD8þ responses; however,
all 30 of the donors responded to at least one antigen, with
most (57%) responding to three or all four. Based on the
percentage of donors responding and median frequency of
IFNgþTcells,weobservedahierarchyof immunodominance
amongst theseantigens,withU90andU54beingco-dominant
followed by U11 and then U39. This is in general agreement
with a previous report where responses against five antigens
(U11, U15, U54, U71 and U90) were analysed in 14 donors,
andU90was found to be themost immunogenic, followed by
U14 and then U54 [25]. It was not clear if the hierarchy
determined in our study was influenced by predominantly
antigen-specific CD4þ or CD8þ T cells, or an even
distributionofboth.Although,when thePepMixTMexpanded
cultureswere analysed for the percentage ofCD3þCD4þ and
CD3þ CD8þ cells, we found that for all four antigens the
majority for cells were CD4þ. Our analysis was limited to
measuring total CD4þ and CD8þ T cells in the expanded
population, rather than also determining antigen specificity,
and it could be argued that the CD4/8 T cell ratio observed in
the expanded population reflects a non-specific expansion
maintaining the same approximate ratio that is present in
PBMC.However, themainlyCD4þTcell responsewassimilar
to that seenwhen PepMixTM expanded cells were analysed for
frequency CD3þCD4þ and CD3þCD8þ cells based on
productionof IFNgafterantigenic stimulation[25]andalso in
agreement with earlier reports [28–30, 32]. Regardless of the
exact composition of the expanded antigen-specific T cells,
our data strongly supports the inclusion of these HHV6B
antigens, particularly U90 and U54, in T cell immunothera-
peutic regimes.
Why the cellular immune response to this herpesvirus is
so low in peripheral blood of latently infected individuals is
unclear. It is likely that, in common with other herpesvirus
[33, 34], HHV6 will encode immunosuppressive proteins.
To date, one HHV6 protein, U21, has been shown to
interfere with the MHC Class I antigen processing and
presentation pathway [35]. HHV6 has also been shown to
have immunomodulatory effects, including infection of
CD4þ T cells and induction of Treg cells [36–38]. These
factors may influence the development of HHV6-specific T
cell responses. The level of HHV6 reactivation may also play
a role. We assume the healthy individuals in this study have a
stable latent infection, and it may be that the levels of virus
reactivation from latency are insufficient to stimulate
generation of high numbers of T cells, while still controlling
reactivation. It would be of interest to carry out serial
analysis of selected donors over a period of time to measure
levels of HHV6-specific T cells, in parallel to monitoring
viral load. Analysis of T cell responses during primary
infection would be of central interest. Higher levels of
HHV6-specific T cells, than seen in healthy individuals, have
been detected in a HSCT patient with active HHV6B
reactivation [25], suggesting that active stimulation by
replicating HHV6B can induce expansion of virus-specific T
cells. A recent study by de Pagter et al. correlating HHV6
reactivation and levels of virus-specific T cells in patients
after HSCT supports this. These authors report that inHSCT
patients where HHV6 reactivation had been evident there
was also an expansion of HHV6-specific T cells, both CD4þ
and CD8þ [39]. Thus, providing encouraging support for
the application of HHV6-specific T cell therapy either by
augmenting such responses by prophylactic treatment or by
adoptive T cell therapy. Indeed, Leen and colleagues have
recently reported the first successful use of HHV6-specific T
cells in adoptive T cell therapy in a patient with high levels of
HHV6 after HSCT [40]. Thus, supporting the need for
continued studies elucidating details of the immune
response to HHV6.
Identifying the immunogenic viral antigens is an impor-
tant first step for development of T cell immunotherapy.
However, it is also important to map and characterise T cell
epitopes within these viral antigens, particularly MHC Class
I restricted peptides. Thus, we extended our study to begin
identifying HHV6B CD8þ T cell epitopes. We focussed on
donors known to respond to U90 and U11, and used an
unbiased approach with regard HLA background. After
stimulation with the relevant PepMixTM, we depleted CD4þ
T cells and screened for peptide reactive CD8þ T cells using
overlapping 15-mer libraries. We identified three putative
Table 1. Summary of putative CD8þ T cell epitopes identiﬁed in HHV6B U90 and U11.
HHV6B antigen 15-mer peptides recognised Sequencea Amino-acidsa Putative HLA restriction Recognition of virus-infected cells
U90 SICDLNIDPSESILL LNIDPSESI 417-425 A1 Yes
KPSKKKIKLDRLPE PSKSKKIKL 758-766 A29 Yes
EANHCFINHFVPIKT NHCFINHFV 903-911 B39 Yes
U11 PLKTQRRHKFPESDS LKTQRRHKF 337-345 C6 Yes
aAmino-acid sequence and positions are based on HHV6B strain Z29 [15].
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novel CD8þ T cell epitopes in U90, termed PSK, NHC and
LNI. These epitopes were predicted to be restricted through
HLA-A29, B39 and A1 respectively. The B39-restricted NHC
epitope sequence conforms to the motif of peptides known
to bind to HLA-B*3901, which have a highly conserved His
at position 2, an aliphatic anchor at position 9 [41]. The LNI
peptide, predicted to be restricted through HLA-A1, gave a
weak response in comparison to the original 15-mer, and as
HLA-A1 tends to have acidic residues at position 3, rather
than position 4 for this peptide [41], it is possible that the
real epitope begins NID and may be a 10-mer. Thus, we have
termed this LNI peptide as a hypothetical epitope. We also
found responses in three donors against the previously
identified HLA B40(60)-restricted epitopes FES and VEE in
U90 [25]. We also identified the epitope LKT in U11, which
was presented by target cells that were HLA-B37, C6 positive.
It is known that there is a strong genetic linkage between
B*3701 and C*0602 [42]. Thus, based on characterised
binding motifs, with B37 requiring an acidic anchor residue
at position 2 and C6 a basic anchor residue at position 2 [41],
and known antigenic peptides [43, 44] we predict that LKT is
restricted through HLA-C7. These HLA alleles predicted to
present the novel putative HHV6B T cell peptides are present
in the caucasian population at average frequencies for A1
14.07%, A29 3.01%, B39 2.03% and C6 9.62% [45],
highlighting their therapeutic relevance. Importantly, T
cells specific for these novel HHV6 immunogenic peptides
were also shown to recognise HHV6B-infected cells. It
should be noted that the T cell populations generated will no
doubt contain other non-HHV6B specific T cells that could
contribute to the recognition observed. However, we do not
believe that this has any significant impact on the data
presented. Low background levels of recognition were
observed, as expected utilising autologous PHA blasts as
target cells in such assays, and a high percentage of virus
infection was observed in all cases. Overall this data supports
the suitability of immunotherapeutic targeting of both U90
and U11 across a range of HLA backgrounds.
For the development and enhancement of adoptive T cell
therapy approaches for diseases driven by HHV6B, a
comprehensive understandingof the overall immune response
to this virus and details such as target antigens and peptides,
and HLA-restricting alleles is vital. The data presented in this
report adds to and expands the existing information, and
supports the on-going efforts to develop T cell immunothera-
py for HHV6 reactivation in transplant settings.
Materials and Methods
Donors, cell lines and virus stocks
PBMCs were obtained from healthy adult volunteers,
ranging in age from 22 to 63 years (median 39 years). The
study was approved by the Liverpool Adult Research Ethics
Committee and informed consent was obtained from all
participating donors according to the Helsinki Declaration.
PBMCs were isolated by Ficoll Hypaque density gradient
centrifugation using Ficoll-PaqueTM Plus (GE Healthcare
Biosciences AB, Little Chalfont, UK). Donors were HLA
typed using a PCR-based protocol by the Clinical Immu-
nology Tissue Typing Laboratory, Royal Liverpool and
Broad Green Hospital Trust, Liverpool, UK. In most cases,
HLA types were obtained for A, B and C alleles, and provided
to two-digit resolution. PHA blasts were generated from
PBMC by treatment with 5mg/mL PHA and culturing in T
cell media (RPMI 1,640 medium with 5% human AB serum,
2mM glutamine, 50 IU/mL penicillin and 50mg/mL
streptomycin). HHV6B virus (strain Z29) was generated
as culture supernatant from SupT1/Z-29 cells [46], obtained
from the HHV-6 Foundation (Santa Barbara, CA, USA).
Briefly, HHV6B-Z29 infected SupT1 cells were maintained
for 6 days in RPMI 1,640media supplemented with 10% FCS
and 2mM glutamine. Virus-containing supernatant was
then harvested, centrifuged at 400g for 5min to remove cells,
before being filtered through a 0.45mm Minisart1 NML
Syringe Filter (Sartorius UK Ltd., Epsom, UK). Virus
containing supernatant was stored in single use aliquots at
808C.
Peptides
Single tube PepMixesTM, containing 15-mer peptides
(overlapping by 11aa) spanning the whole protein for
HHV6B antigens U11, U39, U54 and U90, HCMV antigens
IE1, IE2, pp65 and gB, and BK polyomavirus VP1 were
obtained from JPT technologies (Berlin, Germany). Indi-
vidual 15-mer peptides, overlapping by 11aa, for HHV6B
antigens U11 and U90, were provided by Dr Ann Leen
(Baylor College ofMedicine, Houston, USA). The individual
U11 and U90 15-mer peptides were used to generate mini-
pools of 13–17 peptides, such that there were 30 mini pools
for U11 and 33 for U90, with each 15-mer represented in 2
mini pools [47]. Individual 9-mer peptides for HHV6B U11
and U90 were purchased from Alta Bioscience Ltd.
(Birmingham, UK). All peptides were synthesised at
>70% purity, and stocks were dissolved in DMSO at
10mg/mL and stored at 208C
Intracellular cytokine staining
PBMCs (5 106/mL) were incubated with PepMixesTM
(final concentration 2mg/ml) in a 5ml polystyrene tube at
378C for 2 h in T cell media, before addition of Brefeldin-A
(10mg/mL, Sigma, Gillingham, UK), and incubation
continued for a further 14 h. Controls were unstimulated
PBMC and PBMC stimulated with ConA (5mg/mL).
PBMCs were then washed twice with PBS at 48C, pelleted
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and incubated with a PC5-conjugated anti-CD8 mAb (BD
Biosciences, Oxford, UK) for 20min at 48C before being
fixed with 4% paraformaldehyde. Cells were then permea-
bilised by incubation for 5 minutes with permeabilization
buffer (eBioscience, Hatfield, UK), followed by staining with
a FITC-conjugated anti-IFN-g mAb (BD Biosciences) for
30min at 48C in the dark. Cells were then washed twice with
PBS, resuspended in 0.5mL PBS, before 0.5 106 were
analysed for CD8þ, IFN-gþve cells. Data was acquired on a
BD FACSCalibur using Cell Quest Software, and analysed
using FlowJo software (Treestar).
ELISPOT
ELISPOT analysis was carried out using the Human IFN-g
ELISPOT kit from MABTECH (Stockholm, Sweden). T cell
populations were added to wells at known cell numbers in
duplicate or triplicate in the presence of either PepMixesTM,
peptide mini pools or individual peptides, where the final
concentration of each peptide was 2mg/mL. Plates were
incubated for 16 h, before addition of secondary antibody
and subsequent detection reagents. The number of spot
forming cells (SFC) was then determinedmanually. Controls
in ELISPOT included unstimulated cells (DMSO treated)
and cells stimulated with the BKV VP1 PepMixTM.
ELISA
ELISA for human IFN-g was carried out using an IFN-g
ELISA Ready-Set-Go1 set (eBioscience), according to the
manufacturer’s guidance. Supernatants from T cell assays
were measured directly or diluted as appropriate. Absor-
bance was read using a Multiskan Spectrum microplate
reader (Thermo Scientific, Hemel Hempstead, UK) using
SkanIt software 2.2. The concentration of IFN-g (pg/mL) in
each sample was calculated against the standard curve.
Generation of HHV6B-specific T cells lines
Polyclonal HHV6-specific T cell populations were generated
as follows. PBMCs (2 106) were incubated with PepMix-
esTM (where the final concentration of each peptide was
2mg/mL) or individual peptides at a final concentration of
10mg/mL in 100mL RPMI for 60min at 378C. Cells were
resuspended in T cell media and seeded in a 24-well plate. T
cell cultures were supplemented on day 3with 100 IU/mL IL-
2 (Sigma), which was replenished every 3 days. On day 10
onwards T cells were harvested, counted and used in
subsequent assays. CD8-enriched polyclonal T cell lines were
generated from 10 days polyclonal T cell cultures by
depletion of CD4þ T cells using an EasySepTM Human
CD4 Positive Selection Kit (STEMCELL, Manchester, U.K.)
according to the manufacturer’s instructions. The efficiency
of CD8þ T cell enrichment was analysed by flow cytometry,
and monitoring CD4þ depletion which ranged between
95% and 99%.
Mapping T cell epitopes
Mapping of minimal T cell epitopes was carried out by direct
stimulation of expanded T cell populations, which had been
enriched for CD8þ T cells. PBMCs were reactivated with
individual 15-mer peptides, enriched for CD8þT cells at day
10, before being incubated with overlapping 9-mer peptides
representing the 15-mer peptide and analysis by ELISPOT.
Identification of HLA restriction element
Autologous, partially HLA-matched and HLA mis-matched
PHA blasts or PBMCs were used as targets in T cell assays.
Target cells were loaded with individual peptides (2mg/mL)
for 2 h in volume of 100mL RPMI at 378C, then washed 3
times with RPMI. Peptide-pulsed cells were then resus-
pended in T cell media at 1 105 cells/mL and used as targets
in a T cell assay. Target cells (1 104 cells in 100mL) were
added in triplicate to wells of a 96-well V-bottom plate and
100ml of T cells from short-term in vitro reactivations were
added at an Effector-to-Target (E/T) ratio of 10:1. The
effectors and targets were co-cultured overnight at 378C,
before 100mL of supernatant was harvested and monitored
for IFN-g by ELISA.
T cell recognition of HHV6B Z29-infected cells
PHA blasts (2 106) in 500mL T cell media were infected
with 500mL of HHV6B virus-containing supernatant for
90min at 378C. A further 1mL T cell media was added and
the infection continued. Six days after infection, virus-
infected PHA blasts and comparable mock-infected cells
were counted, resuspended in T cell media at 1 105 cells/
mL and used as targets in a T cell assay. Target cells
(1 104 cells in 100mL) were added in triplicate to wells of a
96-well V-bottom plate and 100ml of T cells from short-term
in vitro reactivations were added at E/T ratios between 20:1
and 5:1. The effectors and targets were co-cultured overnight
at 378C, before 100mL of supernatant was harvested and
monitored for IFN-g by ELISA. Infection of PHA blasts by
HHV6B was confirmed by monitoring visually for cyto-
pathic effects and by immunofluorescence staining with a
mouse–antihuman HHV6B mAb (monoclonal antibody
MAB8535, clone C3108-003; Chemicon). The HHV6B mAb
was used at a dilution of 1:50 in PBS, and incubated with cells
for 90min at 378C in 5% CO2, before being stained with a
secondary antibody (Goat anti-mouse IgG-FITC). Slides
were counter stained DAPI then analysed with a Nikon
fluorescence microscope.
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